<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118490</article-id><article-id pub-id-type="publisher-id">ACM-44374</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_48762339.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  特纳综合征患者骨质疏松研究进展
  Advances in Research on Osteoporosis in Patients with Turner Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>熊</surname><given-names>丽君</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>欣冉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汲</surname><given-names>宝兰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>梅</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>济宁医学院临床医学院，山东 济宁 </addr-line></aff><aff id="aff3"><addr-line>济宁医学院附属医院内分泌科，山东 济宁；中国行为医学生长发育研究中心，山东 济宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3378</fpage><lpage>3383</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  特纳综合征(Turner syndrome, TS)是女性最常见的性染色体异常疾病，患有TS的女性以骨骼异常、身材矮小、子宫和卵巢先天发育不足，心脏异常和神经认知问题等为特征。TS女性的骨量减少、骨质疏松和骨折发生率高于正常女性，鉴于骨质疏松的高患病率，本文就TS患者骨质疏松的危险因素作一综述，并对其管理提出建议。
   Turner syndrome (TS) is the most common sexual chromosomal abnormality in women. Women with TS are characterized by skeletal abnormalities, short stature, underdeveloped uterus and ovaries, heart abnormalities and neurocognitive problems. The incidence of osteopenia, osteoporosis, and fractures in TS women is higher than that of normal women. In view of the high prevalence of osteoporosis, this article reviews the risk factors of osteoporosis in TS patients and makes recommendations for their management.
 
</p></abstract><kwd-group><kwd>特纳综合征，骨质疏松，危险因素，综述, Turner Syndrome</kwd><kwd> Osteoporosis</kwd><kwd> Risk Factors</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>特纳综合征(Turner syndrome, TS)是女性最常见的性染色体异常疾病，患有TS的女性以骨骼异常、身材矮小、子宫和卵巢先天发育不足，心脏异常和神经认知问题等为特征。TS女性的骨量减少、骨质疏松和骨折发生率高于正常女性，鉴于骨质疏松的高患病率，本文就TS患者骨质疏松的危险因素作一综述，并对其管理提出建议。</p></sec><sec id="s2"><title>关键词</title><p>特纳综合征，骨质疏松，危险因素，综述</p></sec><sec id="s3"><title>Advances in Research on Osteoporosis in Patients with Turner Syndrome<sup> </sup></title><p>Lijun Xiong<sup>1</sup>, Xinran Zhang<sup>2,3</sup>, Baolan Ji<sup>2,3</sup>, Mei Zhang<sup>2,3*</sup></p><p><sup>1</sup>Department of Clinical Medicine, Jining Medical University, Jining Shandong</p><p><sup>2</sup>Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining Shandong</p><p><sup>3</sup>Chinese Research Center for Behavior Medicine in Growth and Development, Jining Shandong</p><p><img src="//html.hanspub.org/file/7-1572434x5_hanspub.png?20210809140824925" /></p><p>Received: Jul. 2<sup>nd</sup>, 2021; accepted: Jul. 28<sup>th</sup>, 2021; published: Aug. 5<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/7-1572434x6_hanspub.png?20210809140824925" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Turner syndrome (TS) is the most common sexual chromosomal abnormality in women. Women with TS are characterized by skeletal abnormalities, short stature, underdeveloped uterus and ovaries, heart abnormalities and neurocognitive problems. The incidence of osteopenia, osteoporosis, and fractures in TS women is higher than that of normal women. In view of the high prevalence of osteoporosis, this article reviews the risk factors of osteoporosis in TS patients and makes recommendations for their management.</p><p>Keywords:Turner Syndrome, Osteoporosis, Risk Factors, Review</p><disp-formula id="hanspub.44374-formula128"><graphic xlink:href="//html.hanspub.org/file/7-1572434x7_hanspub.png?20210809140824925"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1572434x8_hanspub.png?20210809140824925" /> <img src="//html.hanspub.org/file/7-1572434x9_hanspub.png?20210809140824925" /></p></sec><sec id="s5"><title>1. 引言</title><p>特纳综合征(Turner syndrome, TS)是一种由部分或全部X染色体单体造成的性染色体疾病，其发病率在1/2500到1/3000之间，其特征是骨骼异常、身材矮小、子宫和卵巢先天发育不足，心脏异常和神经认知问题 [<xref ref-type="bibr" rid="hanspub.44374-ref1">1</xref>]。对于患有TS的青少年和年轻成年患者，骨健康和骨密度是主要关注的问题。TS女性的骨量减少、骨质疏松和骨折发生率高于正常女性 [<xref ref-type="bibr" rid="hanspub.44374-ref2">2</xref>]。低骨密度和骨脆性增加的危险因素很多，包括长期激素缺乏(特别是雌激素缺乏)、X染色体异常(特别是SHOX基因的单倍充足性)和其他环境因素(如骨骼肌发育不良导致的体力活动少)等。鉴于TS中骨质疏松症的高患病率，本文就TS骨质疏松症的危险因素作一综述，并对其管理提出建议。</p></sec><sec id="s6"><title>2. Turner患者骨质疏松的危险因素</title><p>1) 雌激素缺乏原发性性腺功能减退症是TS的主要特征。大约6%的女性有规律的月经周期，而其中90%的女性缺乏青春期发育，出现原发性闭经或青春期停经伴继发性闭经，需要雌激素替代治疗(ERT)。雌激素在骨骼生长增加、成年后骨骼的稳态以及绝经期间减少骨丢失具有重要作用。Nguyen的实验表明，TS患者与对照组相比，雌激素替代治疗(ERT)过晚和雌激素缺乏多年与脊柱和股骨颈平面骨密度、骨矿物表观密度和Z评分降低有关(p &lt; 0.05)，即使在调整了年龄和BMI后也是如此(p &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.44374-ref3">3</xref>]。Nakamura等人也证明了类似的结果，报告称早期雌激素替代治疗组(18岁之前开始)的骨密度显著高于晚期治疗组(18岁或以上开始)。早期治疗组和月经来潮组的骨密度没有显著差异 [<xref ref-type="bibr" rid="hanspub.44374-ref4">4</xref>]。日本的一项多中心回顾性队列研究证明，在15~39岁年龄组中，雌激素对骨密度起决定性作用，有自发月经的女性的骨密度明显高于没有自发月经的女性。在没有自发性月经的女性中，骨密度与雌激素治疗的持续时间相关，并且TS患者的年龄相关性骨丢失发生的时间早于健康的绝经前妇女 [<xref ref-type="bibr" rid="hanspub.44374-ref5">5</xref>]。以上研究均表明雌激素的缺乏是TS患者骨密度低的主要因素之一。</p><p>2) X染色体异常(特别是SHOX基因的单倍充足性) Hansen发现，患有TS的女性皮质孔隙率较低，小梁密度较低，桡骨和胫骨的小梁微结构较差，对生物力学强度的评估也较低。此外，当检查桡骨时，即使在调整身高、青春期年龄、雌激素治疗时间和血清维生素D水平后，TS患者的皮质骨密度仍明显低于对照组，这表明这些骨骼差异与X染色体基因的单倍充足性有关 [<xref ref-type="bibr" rid="hanspub.44374-ref6">6</xref>]，可能是由矮身材同源盒基因(SHOX)缺失或突变引起的，SHOX位于性染色体的假常染色体1区，它编码一种与骨骼生长有关的转录因子。SHOX或其转录调节元件的点突变、缺失或重复复制与骨骼发育不良相关，在一项横断面研究中，发现TS受试者与单纯SHOX单倍体不足的受试者在骨骼几何结构和体积密度方面有很大的相似性 [<xref ref-type="bibr" rid="hanspub.44374-ref7">7</xref>]。根据这些发现，Frederiksen等人强调了SHOX突变对骨微结构的影响，而不是对骨强度的影响 [<xref ref-type="bibr" rid="hanspub.44374-ref8">8</xref>]。</p><p>3) 维生素D缺乏骨密度与维生素D的摄入量直接相关，提高维生素D血清水平是降低老年人骨折风险的有效策略 [<xref ref-type="bibr" rid="hanspub.44374-ref9">9</xref>]。在TS中，目前的研究已经报道低血清维生素D浓度可能导致骨质疏松症，可能是由于心理原因阳光照射不足，维生素D缺乏，导致钙减少和PTH水平的增加 [<xref ref-type="bibr" rid="hanspub.44374-ref10">10</xref>]。TS患者维生素D受体基因多态性也与骨密度降低有关 [<xref ref-type="bibr" rid="hanspub.44374-ref11">11</xref>]。有研究表明，KL和CYP27B1基因均参与维生素D代谢途径，其变体可能导致钙代谢的严重缺陷，变异体之间的基因相互作用导致了TS患者的低骨密度 [<xref ref-type="bibr" rid="hanspub.44374-ref12">12</xref>]。此外，维生素D的生物活性由维生素D受体(VDR)介导，其基因水平与Cdx-2和FokI多态性位点的变异相关，VDR基因表达的下调导致TS患者免疫失衡，影响骨密度 [<xref ref-type="bibr" rid="hanspub.44374-ref13">13</xref>]。</p><p>4) 运动减少 Talia Thompson等人通过亲子报告证明TS青少年的身体活动水平较低，并探讨了活动水平降低的原因，包括与TS相关的身体和心理社会并发症(例如，身材矮小、疲劳、焦虑、视觉空间缺陷) [<xref ref-type="bibr" rid="hanspub.44374-ref14">14</xref>]。波兰TS青少年自我报告的体育活动发现，只有19%的青少年达到每周体育活动的建议水平。在这项研究中，25%的TS青少年医生不建议上体育课(可能是由于心肺功能限制)，另外30%的人不喜欢体育课 [<xref ref-type="bibr" rid="hanspub.44374-ref15">15</xref>]。许多非TS患者的研究报告表明在儿童和成人人群中，体育活动对骨骼健康的益处 [<xref ref-type="bibr" rid="hanspub.44374-ref16">16</xref>]。肌骨相互作用对骨量的增加和维持具有重要意义。当骨受到机械力的压力时，通过骨细胞的反馈回路被设定来增加骨量并改善最大应变部位的微结构。这一过程已经通过前人提出的“机械静态模型”的概要模式进行了概念化 [<xref ref-type="bibr" rid="hanspub.44374-ref17">17</xref>]。另外，局部性的“骨载荷理论”体现为外界冲力，肌肉牵拉等机械负荷影响局部骨结构代谢，与骨密度有着显著的关系 [<xref ref-type="bibr" rid="hanspub.44374-ref18">18</xref>]。</p><p>5) 其他可能的机制TS患者的身体成分、代谢和炎症标志物可能发生显著改变，损害骨骼健康。Gravholt证明，与同龄人相比，TS受试者与对照组相比，瘦体重较低，BMI升高，脂肪质量增加，调节内脏脂肪含量升高、炎症标志物IL-6、IL-8、肿瘤坏死因子a升高，睾酮水平降低 [<xref ref-type="bibr" rid="hanspub.44374-ref19">19</xref>]。另一个可能导致低骨量的因素是GH/IGF-1失衡，GH/IGF-1轴受体内多种激素、受体和信号的调节，任何导致其失衡的原因都可能导致骨质疏松的发生 [<xref ref-type="bibr" rid="hanspub.44374-ref20">20</xref>]。Turner患者易患的腹腔疾病和炎症性肠病等营养性疾病进一步增加患者骨质疏松症风险 [<xref ref-type="bibr" rid="hanspub.44374-ref21">21</xref>]。</p></sec><sec id="s7"><title>3. 治疗管理建议</title><p>对TS患者骨质疏松症的一级和二级预防建议与非TS人群的建议一致。虽然已知这些女性存在骨质疏松症的风险，但除了维持雌激素水平外，不建议对有骨质疏松症风险的妇女进行常规建议以外的其他具体干预措施。骨健康的管理应该注意防治结合，预防骨质疏松应该从儿童时期开始，并定期检测骨密度情况 [<xref ref-type="bibr" rid="hanspub.44374-ref22">22</xref>]。此外，对SHOX基因的深入研究也将为目前的结论添砖加瓦 [<xref ref-type="bibr" rid="hanspub.44374-ref7">7</xref>]。关于TS患者骨质疏松的管理治疗措施尚有争议，已被证明可能对骨质疏松有一定疗效的治疗措施主要包括生长激素治疗，雌激素替代治疗，提供营养补充剂(如钙、维生素D)，生活方式和运动干预。到目前为止，在TS人群中还没有使用双磷酸盐药物的治疗或预防试验。</p><p>1) 生长激素治疗关于生长激素治疗对TS妇女骨密度影响的文献还存在争议。目前还没有随机对照研究比较生长激素和安慰剂的效果。一项对28名TS妇女的回顾性队列研究显示，儿童生长激素治疗与身高增加、骨骼增大和极惯性矩(pMOI)呈正相关。即使没有发现骨密度或微结构参数的差异，较高的pMOI和较大的骨尺寸似乎对骨折起到保护作用 [<xref ref-type="bibr" rid="hanspub.44374-ref23">23</xref>]。一组对32例6至16岁的TS少女的前瞻性研究也证明了类似的结果，在这项研究中，接受生长激素治疗的TS女孩骨折发生率与年龄匹配的未患病儿童人群相同 [<xref ref-type="bibr" rid="hanspub.44374-ref24">24</xref>]。与这些发现一致的是更早的研究，其报告了生长激素对骨密度的积极影响 [<xref ref-type="bibr" rid="hanspub.44374-ref25">25</xref>]。但更多的研究则没有发现生长激素对骨密度的任何关系。到目前为止，在TS中使用GH的建议只是促生长疗法的一部分。</p><p>2) 雌激素治疗 雌激素替代疗法(ERT)是TS治疗的基石，包括青春期诱导、第二性征的初现、子宫正常生长和骨量获得。ERT通常能有效改善青少年TS患者的骨密度，尤其是全身骨密度、髋部骨密度和股骨颈骨密度 [<xref ref-type="bibr" rid="hanspub.44374-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.44374-ref27">27</xref>]。D. Cintron在一项总结了12个随机对照试验和13个观察研究的综述中表明雌激素替代治疗使骨密度基线测量值增加0.09 g/cm<sup>2</sup> (95%CI: 0.04~0.14) [<xref ref-type="bibr" rid="hanspub.44374-ref28">28</xref>]。ERT似乎还会导致TS女性的骨密度发生与普通人群中观察到的相似的发育变化，并将她们的骨密度提高到健康个体的水平，从而改善她们骨折和骨质疏松的风险。T. Nakamura等人在一组100例TS患者(88例原发性闭经(PA)和12例自发性月经周期(MC)组成的研究表明高剂量的雌激素替代治疗对骨密度或骨标记物没有影响，而早期使用(&lt;18岁)显著加快了骨密度的增加 [<xref ref-type="bibr" rid="hanspub.44374-ref4">4</xref>]。PhD等在一组评估口服两种不同剂量17&#223;-雌二醇对青年TS妇女骨密度(BMD)、骨转换生化指标和身体成分影响的实验中得出结论，较高的雌激素剂量对骨密度或骨标记物无显著影响 [<xref ref-type="bibr" rid="hanspub.44374-ref29">29</xref>]。这些研究结果表明，早期开始和持续使用ERT有助于保持小梁骨评分和骨密度，及时的青春期和最佳的骨骼发育可能需要比通常使用的更早地开始雌激素。但青春期前开始ERT对骨骼的影响目前尚不明确，仍需要更多的研究来阐明这一问题。关于给药途径，最近的一项荟萃分析表明，经皮雌激素比口服雌激素对骨量的影响更大 [<xref ref-type="bibr" rid="hanspub.44374-ref30">30</xref>]，然而，在一项随机对照试验中没有报道这种相关性，该试验报告了剂量的滴定而不是给药途径会影响骨密度 [<xref ref-type="bibr" rid="hanspub.44374-ref31">31</xref>]。</p><p>3) 补充钙和维生素D研究表明，即使在激素替代治疗后，骨量仍然不足，如果同时使用激素替代治疗和维生素D，BMD会显著增加 [<xref ref-type="bibr" rid="hanspub.44374-ref32">32</xref>]。丰富的钙和维生素D的摄入对于骨健康是必须的，TS研究小组推荐TS患者在青春期前至少摄入1000毫克元素钙，11岁以后每天至少摄入1200~1500毫克元素钙 [<xref ref-type="bibr" rid="hanspub.44374-ref1">1</xref>]。TS患者护理指南建议对9至11岁的TS女孩进行维生素D缺乏症筛查，此后每2~3年监测一次血清25-OHD，并在必要时用非活性维生素D (麦角钙化醇)进行治疗 [<xref ref-type="bibr" rid="hanspub.44374-ref33">33</xref>]。ELD是一种在增加骨量和改善骨代谢方面优于先前存在的活性维生素D类似物(alfacalidol)，与单独使用ERT相比，联合使用ELD可使骨密度得到更大的改善，ELD可被认为是一种对TS患者的高效辅助治疗 [<xref ref-type="bibr" rid="hanspub.44374-ref34">34</xref>]。</p><p>4) 身体活动和生活方式干预与任何患者一样，强调戒烟和减少酒精摄入是很重要的 [<xref ref-type="bibr" rid="hanspub.44374-ref35">35</xref>]，同时研究表明运动疗法可以提高患者骨密度情况，改善妇女雌激素分泌，对于防治骨质疏松有很好的疗效 [<xref ref-type="bibr" rid="hanspub.44374-ref18">18</xref>]。一项对188名骨质疏松妇女的随机对照实验表明在雌激素替代疗法治疗骨质疏松症的基础上联合运动疗法能够显著提高临床疗效 [<xref ref-type="bibr" rid="hanspub.44374-ref36">36</xref>]。负重运动对于达到和保持骨密度非常重要，应该鼓励。此外.影响骨质疏松风险的共病，如乳糜泻、炎症性肠病和听力问题，应寻求治疗 [<xref ref-type="bibr" rid="hanspub.44374-ref33">33</xref>]。</p><p>5) 双磷酸盐治疗TS研究小组对年轻TS女性的骨质减少的治疗建议中不推荐首先使用双磷酸盐，对于骨质疏松患者存在骨折风险时，推荐使用常规医学治疗。因为TS中皮质骨密度的降低并未被证明会导致骨折的增加，并且双膦酸盐也未被证明能有效增强TS中的皮质骨密度 [<xref ref-type="bibr" rid="hanspub.44374-ref1">1</xref>]。到目前为止，在TS人群中还没有使用这些药物的治疗或预防试验。</p></sec><sec id="s8"><title>4. 结论</title><p>患有特纳综合征的女性患骨质疏松症的风险增加。其原因可能是雌激素缺乏、维生素D代谢异常、身体活动减少等，建议尽早开始雌激素替代治疗并迅速滴定至成人剂量，长期监测激素替代疗法的依从性，定期筛查相关骨质疏松危险因素。对于临床工作而言，加强TS患者骨健康的管理除了药物治疗外，应该关注TS患者的生活方式和心理健康，以便早期采取积极的干预措施来预防TS骨质疏松的发生或发展。</p></sec><sec id="s9"><title>文章引用</title><p>熊丽君,张欣冉,汲宝兰,张 梅. 特纳综合征患者骨质疏松研究进展Advances in Research on Osteoporosis in Patients with Turner Syndrome[J]. 临床医学进展, 2021, 11(08): 3378-3383. https://doi.org/10.12677/ACM.2021.118490</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44374-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bondy, C.A. and Turner Syndrome Study Group (2007) Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group. The Journal of Clinical Endocrinology and Metabolism, 92, 10-25.  
&lt;br&gt;https://doi.org/10.1210/jc.2006-1374</mixed-citation></ref><ref id="hanspub.44374-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gravholt, C.H., Lauridsen, A.L., Brixen, K., et al. (2002) Marked Disproportionality in Bone Size and Mineral, and Distinct Abnormalities in Bone Markers and Calcitropic Hormones in Adult Turner Syndrome: A Cross-Sectional Study. The Journal of Clinical Endocrinology and Metabolism, 87, 2798-2808. &lt;br&gt;https://doi.org/10.1210/jcem.87.6.8598</mixed-citation></ref><ref id="hanspub.44374-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, H.H., Wong, P., Strauss, B.J., et al. (2017) Delay in Estrogen Commencement Is Associated with Lower Bone Mineral Density in Turner Syndrome. Climacteric, 20, 436-441. &lt;br&gt;https://doi.org/10.1080/13697137.2017.1325461</mixed-citation></ref><ref id="hanspub.44374-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, T., Tsuburai, T., Tokinaga, A., et al. (2015) Efficacy of Estrogen Replacement Therapy (ERT) on Uterine Growth and Acquisition of Bone Mass in Patients with Turner Syndrome. Endocrine Journal, 62, 965-970.  
&lt;br&gt;https://doi.org/10.1507/endocrj.EJ15-0172</mixed-citation></ref><ref id="hanspub.44374-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Itonaga, T., Koga, E., Nishigaki, S., et al. (2020) A Retrospective Multicenter Study of Bone Mineral Density in Adolescents and Adults with Turner Syndrome in Japan. Endocrine Journal, 67, 1023-1028.  
&lt;br&gt;https://doi.org/10.1507/endocrj.EJ20-0083</mixed-citation></ref><ref id="hanspub.44374-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Soucek, O., Lebl, J., Snajderova, M., et al. (2011) Bone Geometry and Volumetric Bone Mineral Density in Girls with Turner Syndrome of Different Pubertal Stages. Clinical Endocrinology, 74, 445-452.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2265.2010.03955.x</mixed-citation></ref><ref id="hanspub.44374-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Soucek, O., Zapletalova, J., Zemkova, D., et al. (2013) Prepubertal Girls with Turner Syndrome and Children with Isolated SHOX Deficiency Have Similar Bone Geometry at the Radius. The Journal of Clinical Endocrinology and Metabolism, 98, E1241-E1247. &lt;br&gt;https://doi.org/10.1210/jc.2013-1113</mixed-citation></ref><ref id="hanspub.44374-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Frederiksen, A.L., Hansen, S., Brixen, K. and Frost, M. (2014) Increased Cortical Area and Thickness in the Distal Radius in Subjects with SHOX-Gene Mutation. Bone, 69, 23-29. &lt;br&gt;https://doi.org/10.1016/j.bone.2014.09.001</mixed-citation></ref><ref id="hanspub.44374-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Clifton-Bligh, R.J., et al. (2011) Contribution of a Common Variant in the Promoter of the 1-α-Hydroxylase Gene (CYP27B1) to Fracture Risk in the Elderly. Calcified Tissue International, 88, 109-116.  
&lt;br&gt;https://doi.org/10.1007/s00223-010-9434-4</mixed-citation></ref><ref id="hanspub.44374-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kun, S., Li, L., Yao-Juan, H., et al. (2016) Body Composition and Bone Mineral Status in Patients with Turner Syndrome. Scientific Reports, 6, Article No. 38026. &lt;br&gt;https://doi.org/10.1038/srep38026</mixed-citation></ref><ref id="hanspub.44374-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Barrientos-Rios, R., Frias, S., Velázquez-Aragón, J.A., et al. (2019) Low Bone Mineral Density and Renal Malformation in Mexican Patients with Turner Syndrome Are Associated with Single Nucleotide Variants in Vitamin D-Metabolism Genes. Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology, 35, 772-776. &lt;br&gt;https://doi.org/10.1080/09513590.2019.1582626</mixed-citation></ref><ref id="hanspub.44374-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Anderson, P.H., Lam, N.N., Turner, A.G., et al. (2013) The Pleiotropic Effects of Vitamin D in Bone. Journal of Steroid Biochemistry and Molecular Biology, 136, 190-194. &lt;br&gt;https://doi.org/10.1016/j.jsbmb.2012.08.008</mixed-citation></ref><ref id="hanspub.44374-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Santos, L.O., Laranjeira, R., Borborema, M., et al. (2020) Vitamin D Receptor (VDR) Gene Polymorphisms and Expression Profile Influence upon the Immunological Imbalance in Turner Syndrome. Journal of Endocrinological Investigation, 43, 505-513. &lt;br&gt;https://doi.org/10.1007/s40618-019-01135-1</mixed-citation></ref><ref id="hanspub.44374-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Thompson, T., Zieba, B., Howell, S., Karakash, W. and Davis, S. (2020) A Mixed Methods Study of Physical Activity and Quality of Life in Adolescents with Turner Syndrome. American Journal of Medical Genetics Part A, 182, 386-396. &lt;br&gt;https://doi.org/10.1002/ajmg.a.61439</mixed-citation></ref><ref id="hanspub.44374-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Amedro, P., Tahhan, N., Bertet, H., et al. (2017) Health-Related Quality of Life among Children with Turner Syndrome: Controlled Cross-Sectional Study. Journal of Pediatric Endocrinology and Metabolism, 30, 863-868.  
&lt;br&gt;https://doi.org/10.1515/jpem-2017-0026</mixed-citation></ref><ref id="hanspub.44374-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">朱侨宇, 王兴. 不同运动项目对青少年运动员骨密度影响的差异分析[J]. 吉林体育学院学报, 2020, 36(4): 48-54.</mixed-citation></ref><ref id="hanspub.44374-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rauch, F. and Schoenau, E. (2001) The Developing Bone: Slave or Master of Its Cells and Molecules? Pediatric Research, 50, 309-314. &lt;br&gt;https://doi.org/10.1203/00006450-200109000-00003</mixed-citation></ref><ref id="hanspub.44374-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">周隆, 任兆舟, 张展, 等. 运动疗法对防治绝经后妇女骨质疏松症的疗效分析及对骨密度的影响[J]. 中国妇幼保健, 2020, 35(7): 1270-1273.</mixed-citation></ref><ref id="hanspub.44374-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gravholt, C.H., Hjerrild, B.E., Mosekilde, L., et al. (2006) Body Composition Is Distinctly Altered in Turner Syndrome: Relations to Glucose Metabolism, Circulating Adipokines, and Endothelial Adhesion Molecules. European Journal of Endocrinology, 155, 583-592. &lt;br&gt;https://doi.org/10.1530/eje.1.02267</mixed-citation></ref><ref id="hanspub.44374-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">苏海容, 邓伟民, 黄思敏, 等. GH/IGF-1轴在成年人骨质疏松发生发展和治疗中的作用[J]. 实用医学杂志, 2016, 32(16): 2764-2766.</mixed-citation></ref><ref id="hanspub.44374-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gravholt, C.H., Andersen, N.H., Conway, G.S., et al. (2017) Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. European Journal of Endocrinology, 177, G1-G70. &lt;br&gt;https://doi.org/10.1530/endoabs.49.GS1.1</mixed-citation></ref><ref id="hanspub.44374-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Vierucci, F., Del Pistoia, M., Erba, P., Federico, G. and Saggese, G. (2014) Usefulness of Phalangeal Quantitative Ultrasound in Identifying Reduced Bone Mineral Status and Increased Fracture Risk in Adolescents with Turner Syndrome. Hormones (Athens, Greece), 13, 353-360.</mixed-citation></ref><ref id="hanspub.44374-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nour, M.A., Burt, L.A., Perry, R.J., et al. (2016) Impact of Growth Hormone on Adult Bone Quality in Turner Syndrome: A HR-pQCT Study. Calcified Tissue International, 98, 49-59. &lt;br&gt;https://doi.org/10.1007/s00223-015-0064-8</mixed-citation></ref><ref id="hanspub.44374-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Soucek, O., Schönau, E., Lebl, J., Willnecker, J., Hlavka, Z. and Sumnik, Z. (2018) A 6-Year Follow-Up of Fracture Incidence and Volumetric Bone Mineral Density Development in Girls with Turner Syndrome. The Journal of Clinical Endocrinology and Metabolism, 103, 1188-1197. &lt;br&gt;https://doi.org/10.1210/jc.2017-02381</mixed-citation></ref><ref id="hanspub.44374-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Soucek, O., Lebl, J., Snajderova, M., Kolouskova, S., et al. (2011) Bone Geometry and Volumetric Bone Mineral Density in Girls with Turner Syndrome of Different Pubertal Stages. Clinical Endocrinology, 74, 445-452.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2265.2010.03955.x</mixed-citation></ref><ref id="hanspub.44374-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Li, L., Qiu, X., Lash, G.E., et al. (2019) Effect of Hormone Replacement Therapy on Bone Mineral Density and Body Composition in Chinese Adolescent and Young Adult Turner Syndrome Patients. Frontiers in Endocrinology, 10, 377.  
&lt;br&gt;https://doi.org/10.3389/fendo.2019.00377</mixed-citation></ref><ref id="hanspub.44374-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, H.H., Wong, P., Strauss, B.J., et al. (2017) Delay in Estrogen Commencement Is Associated with Lower Bone Mineral Density in Turner Syndrome. Climacteric: The Journal of the International Menopause Society, 20, 436-441.  
&lt;br&gt;https://doi.org/10.1080/13697137.2017.1325461</mixed-citation></ref><ref id="hanspub.44374-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Cintron, D., Rodriguez-Gutierrez, R., Serrano, V., et al. (2017) Effect of Estrogen Replacement Therapy on Bone and Cardiovascular Outcomes in Women with Turner Syndrome: A Systematic Review and Meta-Analysis. Endocrine, 55, 366-375. &lt;br&gt;https://doi.org/10.1007/s12020-016-1046-y</mixed-citation></ref><ref id="hanspub.44374-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Cleemann, L., Holm, K., Kobbernagel, H., et al. (2017) Dosage of Estradiol, Bone and Body Composition in Turner Syndrome: A 5-Year Randomized Controlled Clinical Trial. European Journal of Endocrinology, 176, 233-242.  
&lt;br&gt;https://doi.org/10.1530/EJE-16-0582</mixed-citation></ref><ref id="hanspub.44374-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Zaiem, F., Alahdab, F., Al Nofal, A., Murad, M.H. and Javed, A. (2017) Oral versus Transdermal Estrogen in Turner Syndrome: A Systematic Review and Meta-Analysis. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 23, 408-421.  
&lt;br&gt;https://doi.org/10.4158/EP161622.OR</mixed-citation></ref><ref id="hanspub.44374-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Torres-Santiago, L., Mericq, V., Taboada, M., et al. (2013) Metabolic Effects of Oral versus Transdermal 17β-Estradiol (E): A Randomized Clinical Trial in Girls with Turner Syndrome. The Journal of Clinical Endocrinology and Metabolism, 98, 2716-2724. &lt;br&gt;https://doi.org/10.1210/jc.2012-4243</mixed-citation></ref><ref id="hanspub.44374-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Tsuburai, T., Nakamura, T., Yoshikata, H., Miyagi, E. and Sakakibara, H. (2018) Eldecalcitol Increases Bone Mass in Patients with Turner Syndrome Who Have Insufficient Bone Mass Acquisition after Estrogen Replacement Therapy. Endocrine Journal, 65, 629-638. &lt;br&gt;https://doi.org/10.1507/endocrj.EJ17-0498</mixed-citation></ref><ref id="hanspub.44374-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">American Academy of Pediatrics (2017) Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome. Pediatrics, 140, e20172626. &lt;br&gt;https://doi.org/10.1542/peds.2017-2626</mixed-citation></ref><ref id="hanspub.44374-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Shiraki, M., Saito, H. and Matsumoto, T. (2012) Eldecalcitol Normalizes Bone Turnover Markers Regardless of Their Pre-Treatment Levels. Current Medical Research and Opinion, 28, 1547-1552.  
&lt;br&gt;https://doi.org/10.1185/03007995.2012.712506</mixed-citation></ref><ref id="hanspub.44374-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Nachtigall, M.J., Nazem, T.G., Nachtigall, R.H. and Goldstein, S.R. (2013) Osteoporosis Risk Factors and Early Life-Style Modifications to Decrease Disease Burden in Women. Clinical Obstetrics and Gynecology, 56, 650-653.  
&lt;br&gt;https://doi.org/10.1097/GRF.0b013e3182aa1daf</mixed-citation></ref><ref id="hanspub.44374-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">李旭卿, 陶丽娜, 任洪叶. 雌激素替代疗法联合运动疗法对妇女绝经后骨质疏松症的影响[J]. 检验医学与临床, 2016, 13(21): 3099-3101.</mixed-citation></ref></ref-list></back></article>